New PET scan could better spot prostate cancer spread

NCT ID NCT06099093

Recruiting now Diagnosis Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a new type of PET scan (18F-DCFPyL PSMA-PET) can show prostate cancer lesions as well as the standard scan (68Ga-PSMA-11 PET/CT) in 30 men with advanced prostate cancer who are receiving a targeted radiation therapy (177Lu-vipivotide tetraxetan). The goal is to see if the new scan is a reliable option for monitoring the disease. Participants will get the experimental scan before starting their standard treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 18F-DCFPyL (a radioactive tracer for PET imaging)
What this could lead to: If successful, this imaging method could offer a more accessible or effective way to monitor prostate cancer spread during treatment.
What could go wrong: This is a small pilot study (30 people) comparing two imaging scans, not testing a new treatment. The new scan may not prove better or more practical than the existing one.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA PROSTATE CANCER

Contacts and locations

Locations

Brigham and Womens Hospital
RECRUITING

Boston, Massachusetts, 02215, United States
Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.